vs
Side-by-side financial comparison of Allegion (ALLE) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $1.0B, roughly 1.1× Allegion). Allegion runs the higher net margin — 13.4% vs -127.8%, a 141.2% gap on every dollar of revenue. On growth, Allegion posted the faster year-over-year revenue change (9.7% vs -2.5%). Over the past eight quarters, Allegion's revenue compounded faster (3.5% CAGR vs 1.3%).
Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door closers, controls, and exit devices; locks, locksets, portable locks, and key systems and services; electronic security products and access control systems; time, attendance, and workforce productivity systems; doors and door systems; and other accessories. The company sells its products and solutions to end-users in commercial, institutional, and residential facili...
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
ALLE vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.1B |
| Net Profit | $138.1M | $-1.4B |
| Gross Margin | 44.0% | 32.6% |
| Operating Margin | 18.9% | -116.0% |
| Net Margin | 13.4% | -127.8% |
| Revenue YoY | 9.7% | -2.5% |
| Net Profit YoY | -6.8% | -3093.9% |
| EPS (diluted) | — | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $1.1B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $941.9M | $1.0B | ||
| Q4 24 | $945.6M | $1.1B | ||
| Q3 24 | $967.1M | $1.1B | ||
| Q2 24 | $965.6M | $1.1B |
| Q1 26 | $138.1M | — | ||
| Q4 25 | $147.5M | $-1.4B | ||
| Q3 25 | $188.4M | $7.5M | ||
| Q2 25 | $159.7M | $-8.4M | ||
| Q1 25 | $148.2M | $-6.4M | ||
| Q4 24 | $144.1M | $-44.4M | ||
| Q3 24 | $174.2M | $-21.0M | ||
| Q2 24 | $155.4M | $-108.4M |
| Q1 26 | 44.0% | — | ||
| Q4 25 | 44.5% | 32.6% | ||
| Q3 25 | 45.8% | 36.1% | ||
| Q2 25 | 45.6% | 34.4% | ||
| Q1 25 | 44.9% | 37.6% | ||
| Q4 24 | 44.1% | 33.9% | ||
| Q3 24 | 44.7% | 37.2% | ||
| Q2 24 | 44.4% | 37.0% |
| Q1 26 | 18.9% | — | ||
| Q4 25 | 20.3% | -116.0% | ||
| Q3 25 | 21.8% | 7.0% | ||
| Q2 25 | 21.5% | 4.3% | ||
| Q1 25 | 20.9% | 4.5% | ||
| Q4 24 | 19.5% | 10.0% | ||
| Q3 24 | 22.2% | 7.4% | ||
| Q2 24 | 21.6% | -2.5% |
| Q1 26 | 13.4% | — | ||
| Q4 25 | 14.3% | -127.8% | ||
| Q3 25 | 17.6% | 0.7% | ||
| Q2 25 | 15.6% | -0.8% | ||
| Q1 25 | 15.7% | -0.6% | ||
| Q4 24 | 15.2% | -3.9% | ||
| Q3 24 | 18.0% | -1.9% | ||
| Q2 24 | 16.1% | -10.2% |
| Q1 26 | — | — | ||
| Q4 25 | $1.70 | $-10.23 | ||
| Q3 25 | $2.18 | $0.05 | ||
| Q2 25 | $1.85 | $-0.06 | ||
| Q1 25 | $1.71 | $-0.05 | ||
| Q4 24 | $1.65 | $-0.32 | ||
| Q3 24 | $1.99 | $-0.15 | ||
| Q2 24 | $1.77 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $308.9M | — |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $2.1B | $2.9B |
| Total Assets | $5.3B | $8.5B |
| Debt / EquityLower = less leverage | 0.97× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $308.9M | — | ||
| Q4 25 | $356.2M | — | ||
| Q3 25 | $302.7M | $432.1M | ||
| Q2 25 | $656.8M | $454.2M | ||
| Q1 25 | $494.5M | $409.9M | ||
| Q4 24 | $503.8M | $558.8M | ||
| Q3 24 | $878.9M | $1.5B | ||
| Q2 24 | $747.5M | $542.8M |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $2.9B | ||
| Q3 25 | $1.9B | $4.4B | ||
| Q2 25 | $1.8B | $4.5B | ||
| Q1 25 | $1.6B | $4.4B | ||
| Q4 24 | $1.5B | $4.3B | ||
| Q3 24 | $1.6B | $4.6B | ||
| Q2 24 | $1.4B | $4.5B |
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.2B | $8.5B | ||
| Q3 25 | $5.2B | $10.1B | ||
| Q2 25 | $4.9B | $10.1B | ||
| Q1 25 | $4.6B | $9.8B | ||
| Q4 24 | $4.5B | $9.6B | ||
| Q3 24 | $5.0B | $11.2B | ||
| Q2 24 | $4.8B | $10.4B |
| Q1 26 | 0.97× | — | ||
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 1.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $101.3M | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | 2.0% | 2.4% |
| Cash ConversionOCF / Net Profit | 0.73× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $101.3M | — | ||
| Q4 25 | $240.1M | $175.4M | ||
| Q3 25 | $229.5M | $51.7M | ||
| Q2 25 | $209.7M | $75.9M | ||
| Q1 25 | $104.5M | $-64.5M | ||
| Q4 24 | $219.0M | $312.6M | ||
| Q3 24 | $231.9M | $42.2M | ||
| Q2 24 | $173.0M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $200.5M | $148.6M | ||
| Q3 25 | $209.8M | $29.8M | ||
| Q2 25 | $192.0M | $56.7M | ||
| Q1 25 | $83.4M | $-90.0M | ||
| Q4 24 | $194.9M | $274.9M | ||
| Q3 24 | $212.0M | $15.1M | ||
| Q2 24 | $152.1M | $-18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 13.4% | ||
| Q3 25 | 19.6% | 2.9% | ||
| Q2 25 | 18.8% | 5.4% | ||
| Q1 25 | 8.9% | -8.6% | ||
| Q4 24 | 20.6% | 24.2% | ||
| Q3 24 | 21.9% | 1.4% | ||
| Q2 24 | 15.8% | -1.8% |
| Q1 26 | 2.0% | — | ||
| Q4 25 | 3.8% | 2.4% | ||
| Q3 25 | 1.8% | 2.1% | ||
| Q2 25 | 1.7% | 1.8% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 2.5% | 3.3% | ||
| Q3 24 | 2.1% | 2.5% | ||
| Q2 24 | 2.2% | 2.7% |
| Q1 26 | 0.73× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.22× | 6.89× | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 1.52× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALLE
| Allegion Americas | $809.9M | 78% |
| Allegion International | $223.7M | 22% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
